Ronald Van Vollenhoven, ACR 2021: Post Hoc Analysis of BIIB059 in Systemic Lupus Erythematosus
It was a pleasure to speak with Professor Ronald Van Vollenhoven (Amsterdam UMC, Amsterdam, the Netherlands) to discuss his post hoc analysis of the LILAC clinical trial, investigating BIIB059 in participants with systemic lupus erythematosus (NCT02847598).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study.’ (ABSTRACT NUMBER: 1747) was presented at the ACR Convergence, 5-9 November 2021.
- What is BIIB059 and what is the rationale for its use in the treatment of patients with systemic lupus erythematosus? (0:15)
- Could you give us a brief overview of the LILAC clinical trial and its findings? (1:01)
- What was the rationale for this post hoc analysis, and what definitions of joint manifestations were used? (2:08)
- What were the findings of the analysis? (3:12)
- What will be the next step in the clinical development of BIIB059 in this indication? (4:57)
Disclosures: Ronald Van Vollenhoven discloses research support (institutional grants): BMS, GSK, Lilly, UCB; support for educational programs (institutional grants): Pfizer, Roche; consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB; speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, Janssen, Pfizer, UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!